CEOInterviews.AI
Start App
Try: AI strategy tariffs earnings guidance layoffs interest rates growth

Rainer Blair

President, Chief Executive Officer & Director, Danaher Corporation

Search every verified Rainer Blair interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. Rainer Blair, President and CEO of Danaher, discussed the company's second-quarter 2026 performance during its earnings call on July 23, 2026. He noted that bioprocessing consumables revenue was lighter than expected due to delays in large chromatography resin shipments, while expressing confidence in a multi-year capital expenditure cycle driven by biologic therapeutics demand and reshoring dynamics. Blair also cited stronger biotech funding, improved commercial execution at Abcam, and early signs of AI-related demand for automation as factors supporting the company's decision to raise its full-year life science guidance. At the 2026 Danaher Summit on Bioprocessing in June, Blair addressed manufacturing bottlenecks in biologic therapies, describing manufacturing as a "rate-limiting step for innovation." He highlighted challenges in scaling cell and gene therapies, noting 2,100 clinical trials underway, and called for greater integration of digital tools into regulated workflows. In earlier appearances, Blair announced Danaher's partnership with the Human Immunome Project as its preferred tools partner and discussed a collaboration with the University of Oxford and Cepheid to develop a sepsis diagnostic test.

Recent appearances

The summary and quote tags on this profile are produced with AI assistance from verified, first-person interview transcripts, then checked by our team to confirm the speaker's identity and the accuracy of every quote. See how we verify →